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Background: Women have higher mortality than men after mitral regurgitation (MR) surgery. To ascertain gender differences with percutaneous 
mitral valve repair, we compared baseline characteristics, safety and effectiveness at 1 y in 128 men and 83 women with MR 3+/4+ enrolled in the 
EVEREST II High Risk Cohort (EIIHRC).
Methods: High risk was defined as STS score ≥ 12% or pre-specified risk factors. Major adverse events (MAE) were death, myocardial infarction, 
stroke and other events. Effectiveness outcomes included changes in left ventricular end-diastolic (LVEDV) and end-systolic volumes (ESV), ejection 
fraction (EF) and MR severity.
Results: At baseline women (age 76.4±8.4 y) were similar to men (75.4±12.7 y) except for smaller LV volumes. When indexed for BSA, LV volumes 
were similar. Functional MR was present in 70%. After PMVR, MR improvement and MAE rates were similar. At 1 y, women had a slightly greater 
reduction in LVESV, with increase in LVEF, whereas men had a slight decrease in LVEF.
Conclusion: In the EIIHRC, women treated with MitraClip had similar MR improvement without higher MAE. Although smaller baseline LV volumes 
suggested an earlier stage of disease, indexed LV volumes were similar. The greater improvement in LVEF suggests that lower LV volumes should be 
thresholds for treatment in women. 
M(N=128) W(N=83) P
BASELINE
STS Score (%) 11.6±7.1 13.2±8.9 ns
NYHA III/IV(%) 82.8 90.4 ns
LVEDV (ml) 173.8±45.7 138.9±51.3 <0.05
LVEDVI (ml/m2) 89.1±22.5 82.2±28.3 0.06
LVESV (ml) 91.8±39.8 72.9±43.5 <0.05
LVESVI (ml/m2) 47.1±20.5 42.9±24.4 ns
LVEF (%) 48.5±12.9 50.3±14.9 ns
RESULTS
MAE- 30d/1 y (%) 17.2/40.6 26.5/36.1 ns
MR ≤ 2+ 1 y (%) 81.2 82.5 ns
LVEDV (ml) 1 y change -20.4±31.0 -22.5±30.9 ns
LVESV (ml) 1 y change -5.8±22.7 -13.2±24.5 0.08
LVEF (%) 1 y change -2.7±9.2 1.0±10.7 <0.05
